Toronto, Ontario - (NewMediaWire) - March 04, 2019 - NexTech AR Solutions (the “Company” or “NexTech”) (CSE: NTAR) (OTC: NEXCF)(FSE:N29) today announced that its CEO, Evan Gappelberg, is scheduled to appear live on Cheddar TV this afternoon at 1:10pm ET.Gappelberg will be showcasing NexTech’s AR for eCommerce technology, including the new ‘Try-It-On’ functionality and updated user experience, as well as sharing his predictions for the future of augmented reality and the eCommerce industry.Viewers can tune into the Cheddar news segment by live streaming on Cheddar’s website or downloading the Cheddar app in the Apple Store or Google Play.Cheddar is the leading post-cable, live-streaming video news network focused on covering the most innovative executives, founders, products, and technologies transforming our lives and economy.About NexTech AR Solutions Corp.NexTech is bringing augmented reality (AR) to the Cannabis industry and to the masses by creating an AR ecosystem featuring eCommerce solutions for websites, AR learning and education tools, and AR live streaming for events. With just a few lines of embed code, the Company’s patent-pending technology can integrate into existing eCommerce platforms, providing retailers with a highly scalable platform that increases customer engagement and sales. To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.On behalf of the Board of NexTech AR Solutions Corp.“Evan Gappelberg”CEO and DirectorThe CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.For further information, please contact: Evan Gappelberg Chief Executive Officer info@nextechar.com Media contact: Erin Hadden FischTank Marketing and PR ehadden@fischtankpr.com

Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the RetinaLONG BEACH, CA - (NewMediaWire) - March 04, 2019 - Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Noramco, Inc. (Noramco) for the manufacturing and scale-up of Nemus’ proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi. Noramco is a recognized, global producer and provider of controlled substances, including cannabinoids, to the pharmaceutical industry.Unlike a prodrug which must be metabolized into the active drug form, an analog has its own intrinsic pharmaceutical activity. Early animal studies of the analog, cannabidiol-valine-hemisuccinate (CBDVHS), have demonstrated improved bioavailability when compared to CBD, based on chemical modifications to the molecule utilizing amide ester bioengineering developed at the University of Mississippi. These attributes, including cannabinoid-based neuroprotection, could be especially important in ocular diseases, where penetrance into the posterior chamber of the eye could potentially expand therapeutic options into diseases of the retina, like macular degeneration and diabetic retinopathy. “Noramco is looking forward to working with Nemus and helping to advance the unique analog CBDVHS through process development and cGMP manufacturing,” commented Bill Grubb, Chief Innovation Officer and Vice-President of Global Business Development. “Contracting with Noramco signals the launch of the CBD-analog program to advance this candidate molecule into pre-clinical development, with a near-term goal to conduct clinical trials to address diseases of the eye,” noted Brian Murphy, M.D., CEO-CMO of Nemus. “Noramco has particular expertise in working with cannabidiol and CBD-derivatives, making them a strategic part of the CBDVHS development plan.” About NoramcoNoramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. The company offers cannabinoids and other APIs for use in abuse deterrence, attention deficit disorder, pain management, and addiction management. Established in 1979, Noramco maintains production and R and Neuhausen, Switzerland; and accesses agricultural operations in Tasmania through an affiliate, Tasmanian Alkaloids. Additional information about Noramco can be obtained by visiting Noramco’s web site at www.Noramco.comAbout Nemus Bioscience, Inc.Nemus is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary synthetic compounds, alone or in combination with corporate partners. Nemus is part of the Emerald Health group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.For more information, visit www.nemusbioscience.comFORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product development, business strategy, product milestones, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations ...

Denver, CO - (NewMediaWire) - March 04, 2019 - Ubiquitech Software Corp. (OTC: UBQU), through its operating subsidiary HempLifeToday.com, today announced its fiscal year end 2018 financial results. Revenues for the year were $3,760,099, and the company had net income of $5,275 for the year ending November 30, 2018.CEO, James Ballas, said: “We are extremely happy to report company results for the fiscal year end 2018. As CEO, I am well aware that results have leveled off over the last few quarters and this is due to the fact that the company continued to invest heavily in growth strategies while regulatory and industry conditions remained challenging. The company will continue to adjust and invest throughout the first half of the current fiscal year. The CannazALL brand recognition initiatives currently being developed will continue to solidify our foothold in the growing CBD marketplace, and we expect improved growth now that favorable legislation has been enacted. With our investment in the company we look forward to improving and expanding our customer support, increasing the speed in which customers receive products, improving our customer online experience, adding new CannazALL CBD products, increasing our advertising budgets and exploring new ad platforms, and announcing phase two of our extremely popular Ambassador Program. The entire staff at HempLife Today is working hard and we firmly believe that we are on the right track to achieve all of our stated goals for the company. Please bear with us as we continue to build the company and we will have lots of exciting news to come, including updates on our name and symbol change which we know you all are waiting for.”About Ubiquitech Software CorpUbiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, DirectResponse (DRTV) Television, Radio, Internet Content, and traditional marketing to drive traffic to the new and emerging multi-billion dollar industries like its subsidiaries HempLifeToday™ and CryptoBuy.comAbout HempLife Today™HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Concentrated Oils, GelCaps, Skin Salve, e-liquid, and CannazALL Pets™ CBD products all offered @ www.HempLifeToday.comAbout CryptoBuyCryptoBuy.com focuses on the burgeoning new world of Crypto Currencies and is created to be a service to persons interested in tracking and trading the many existing and future Crypto Currencies worldwide.This press release contains forward-looking statements. Words such as "expects", "intends'', "believes'', and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the after the date of this release.Contact / Investor relations IR@UbiquitechSoftware.com

San Diego, CA - (NewMediaWire) - March 04, 2019 - Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher”), a company specializing in the development of Internet of Things (IoT) and Artificial Intelligence enabled networking and tracking technologies, including its GopherInsight global mesh network technology platform for both mobile and fixed solutions, today announced it has completed its initial testing of its MESH Radio system with satisfactory results.These initial tests were conducted in order to evaluate the functionality and performance of Gophers MESH radio system and included an evaluation of radio spectrum as defined by the Company’s Design Verification Testing (DVT) protocol. Test results included… "This is an exciting moment for us as we see our MESH system realizing our plan under rigorous testing conditions, " stated Danny Rittman, Gopher CTO. "OTA testing is the first stage of architecture radio testing. With this initial stage complete, we now shift our focus towards improving the system’s results primarily through firmware and antennas. Additionally, in a few weeks, testing of power consumption will also be conducted in order to ensure substantial battery life."About Gopher Protocol Inc.Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher”) (http://gopherprotocol.com/) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. Gopher has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. Gopher’s system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. Gopher envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.https://www.avant-ai.netForward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.Contact: Dr. Danny Rittman, CTO Gopher Protocol Inc. Media: press@gopherprotocol.com

Statement highlights: Oscillometric devices, which use an electronic pressure sensor within the blood pressure cuff, can reduce human error and the risk to the environment from older devices which use mercury. Patients who measure their blood pressure at home should use a device with an upper arm cuff that has been checked for accuracy by a healthcare provider. Embargoed 4 a.m. CT / 5 a.m. ET Monday, March 4, 2019 (NewMediaWire) - March 04, 2019 - DALLAS - The accurate measurement of blood pressure is essential for the diagnosis and management of hypertension, a major risk factor for heart disease and stroke, according to an updated American Heart Association scientific statement on blood pressure measurement in humans, published in the American Heart Association journal Hypertension. The statement, which updates a previous statement on the topic published in 2005, provides an overview of what is currently known about blood pressure measurement. and supports recommendations in the 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure The auscultatory method – where a healthcare provider uses a blood pressure cuff, a stethoscope and a mercury sphygmomanometer (device that measures blood pressure) – has been the gold standard for office blood pressure measurement for several decades. The mercury sphygmomanometer has a simple design and is not subject to substantial variation across models made by different manufacturers. However, mercury devices are no longer being used due to environmental concerns about mercury. “Many oscillometric devices, which use an electronic pressure sensor within the blood pressure cuff, have been validated (checked for accuracy) which allow for accurate blood pressure measurement in the healthcare office settings while reducing human errors associated with the auscultatory approach,” said Paul Muntner, Ph.D., chair of the writing group for the scientific statement. “Additionally, newer automated oscillometric devices can obtain multiple measurements with the single push of a button, which can be averaged to better estimate blood pressure,” said Muntner, who is also a professor at the University of Alabama at Birmingham. The statement also summarizes current knowledge about ambulatory blood pressure monitoring, which is done when a patient wears a device which measures their blood pressure throughout the day to identify white coat hypertension and masked hypertension. Substantial data have been published since the last Scientific Statement in 2005 showing the importance of measuring blood pressure outside of the clinic setting. White coat hypertension, when blood pressure is raised in the healthcare office setting but not at other times and masked hypertension where blood pressure is normal in the healthcare office setting but raised at other times. As detailed in the Scientific Statement, patients with white coat hypertension may not have an increased risk for cardiovascular disease and may not benefit from initiating antihypertensive medication. In contrast, patients with masked hypertension have a substantial increased risk for cardiovascular disease. The 2017 hypertension guideline also recommends conducting ambulatory blood pressure monitoring to screen for white coat hypertension and masked hypertension in clinical practice. The American Heart Association continues to recommend patients measure their blood pressure at home using a blood pressure device with an upper arm cuff that has been checked for accuracy by a healthcare provider. Co-authors are Daichi Shimbo, M.D., Vice-Chair; Robert M. Carey, M.D.; Jeanne B. Charleston, Ph.D.; Trudy Gaillard, Ph.D.; Sanjay Misra, M.D; Martin G. Myers, M.D.; Gbenga Ogedegbe, M.D.; Joseph E. Schwartz, Ph.D.; Raymond R. Townsend, M.D.; Elaine M. Urbina, M.D., M.S.; Anthony J. Viera, M.D., M.P.H.; William B. White, M.D.; and Jackson T. Wright, Jr, M.D., Ph.D. Additional Resources: Multimedia available for download on the right column of the release ...

NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

Phoenix, AZ - (NewMediaWire) - March 01, 2019 - Phoenix, AZ - (NewMediaWire) - March 01, 2019 - For The Earth Corporation (the “Company”) (OTC: FTEG) is excited to provide acquisition update.Acquisitions Update:“I would like to comment on the latest announcement regarding For The Earth’s acquisition of the Chow brand. As we all know, when one company acquires another (or when a company is only acquiring another companies brand name), there is always apprehension from both parties. After the agreement was signed, I decided it wasn’t the right fit for FTEG. The number of vending machines that Vliso’s management team wanted to launch {in 2019} was extremely aggressive. This in turn would not allow for other acquisitions, development of new products, and marketing campaigns. It would not support FTEG in creating strong revenues and would have forced our focus from long term shareholder value. “We will concentrate efforts on the launch of our Las Vegas vending machines, kiosks and inline retail store,” said Nelson Grist, President and CEO of For The Earth Corporation. “Vlsio is a great startup company, with great a management team who are young and highly skilled, I wish them well!”If you have any questions, please send an email to the FTEG Investment Team.infofteg@gmail.comAbout For The Earth CorporationFor The Earth Corporation is an emerging integrated CBD producer and retailer in the United States. The Company is in the process of establishing a vertical framework that will extend from cultivation to extraction and production to a strategic retail footprint. that includes multiple locations, featuring mall kiosks, vending machines, e-commerce, and full store locations serving both the human and pet CBD markets. Two mall leases have been signed recently in Las Vegas, with another vending machine location secured in New York City. The Company plans to expand its New York vending machine penetration by the end of 2019. In addition, the Company has begun early-stage work to establish a state-of-the-art CBD extraction and production facility in Eugene, OR.Forward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See For The Earth’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Press & Media Inquiries: EHC Branding Agency Info@EHCBrandingAgency.com (626) MJ-BRAND For The Earth Corporation 20 E Thomas Rd. Phoenix, AZ 85012 USA Contact: Nelson Grist Telephone: 602 502-0602 Email: infofteg@gmail.com

Pittsburgh PA - (NewMediaWire) - March 1, 2019 - Unique Foods Corporation (OTCPK: UPZS) announces the removal of a $495,000 debt that has been carried on the corporate books for the past sixteen quarters. This debt has been deemed by corporate counsel and accountants to not be the responsibility of Unique Foods Corp and should be removed from the past and omitted from future filings.This “Note 5” section will be removed from all past filings along with $495,000 debt from the balance sheet “Note Payable to a Related Party Individual”. Over the next few months all of the previous filings that included this debt will be amended and when the 2018 year end financials are posted the $495k will be omitted.Note 5 – Note Payable to a Related Party IndividualPursuant to the Company’s variable interest entity relationship with a California based restaurant, the Company incurred a promissory note in the amount of $495,000. The amount payable to the individual, related through the variable interest entity relationship as the mother of the managing member of Credo Ventures, LLC who loaned the monies to Credo Ventures, LLC, at September 30, 2018 is $495,000.The promissory note bears interest of 10% per annum, has equal monthly payments payable of $10,517 over sixty months maturing on October 17, 2020 and the restaurant equipment is the collateral.James C. Vowler, President & CEO of Unique Foods Corp., stated, “When the debt was occurred it was paid directly to Credo Ventures and as a result, Unique Foods Corp should not have registered the debt on our books. The removal of this debt is certainly a positive step for the company and combined with all of the other exciting achievements going on with Unique 2019 is starting off great.”About Unique Foods Corporation:Unique Foods Corp. partnered with Jack Brewer (Unique Foods Brand Ambassador) & Brewer Media & Entertainment Group in October of 2017. Brewer Media Group was brought on to help build all aspects of the many Unique brands. With a primary focus on the increase of online and retail sales, social media presence and overall content, public persona and awareness, acquire acquisition opportunities and much more. The company has three wholly owned subsidiaries Jose Madrid Salsa, Unique Tap House and PopsyCakes and a Licensing agreement with Christopher Street Products.The Unique Tap House 39809 Avenida Acacias, Murrieta, CA 92563, To Book your office or birthday party, special event, group reservations or to order food call (951) 445-4769.Twitter: @ChristopherS_T_@uniquefoodscorp@MadridSalsa@PopsyCakes@UniquePizzaTapHInstagram: instagram.com/unique_foods_corpWebsites:Unique Foods Corp.: http://www.UniqueFoods.coJose Madrid Salsa: http://www.JoseMadridSalsa.comPopsyCakes: http://www.PopsyCakes.comChristopher Street Products: http://www.ChristopherStreet.NYCSafe Harbor Act: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward- looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions. There are no financials in this press release so this is not needed and undermines the release.For Unique Foods Corp. Investor Relations contact Complete Advisory Partners Phone: (586) 228- 2290 Fax: (586) 228-6920 capinc@comcast.net http:/www.capinc.net

New York - (NewMediaWire) - March 1, 2019 - Weyland Tech Inc. (WEYL) (“Weyland” or the “Company”) will host a conference call to discuss the general overview of the business and recent updates on strategic and corporate initiatives as well as an update on its eWallet business.Weyland will host the call at 12:00 pm. Eastern Time (11:00 pm. Central Time) on Thursday, March 7, 2019. To participate investors may dial-in on 1 (701) 801-1211 and enter the access code: 873-908-258.The conference call will also be made available for replay at 1 (701) 801-1218 with the access code: 873-908-258.The Company will be answering questions provided in advance by shareholders and requests that those be sent by email to: cc@weyland-tech.com.Additionally, callers are asked to join the call promptly at 12:00 PM Eastern Time.About Weyland Tech Inc.Weyland Tech is a global provider of mobile business applications. The Company operates a Platform-as-a-Service (“PaaS”) software used on mobile ‘smartphones’. The PaaS platform offers a mobile presence to Small-to-Medium-Sized- Businesses (“SMB’s”) in emerging markets, with partnerships on 3 continents and growing. The PaaS platform, offered in 14 languages with over 70 integrated modules, enables SMB’s to create native mobile applications (“apps”) for Apple’s iOS and Google Android without technical knowledge or background, empowering SMB’s to increase sales, reach more customers and promote their products and services in an easy, affordable and efficient manner.In May 2018, the Company expanded its portfolio to fintech applications with the launch of its AtoZPay mobile payments platform. The mobile wallet launched in the world’s 4th most populous country, Indonesia, and is already experiencing rapid growth in transactions taking place on the platform.Safe Harbor StatementThis release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.For further information contact: Howard Gostfrand American Capital Ventures, Inc. President Office: 305-918-7000 Email: hg@amcapventures.com www.amcapventures.com

Brookfield, WI - (NewMediaWire) - March 01, 2019 - Trident Brands Inc. (OTCQB: TDNT), a biotech and nutraceutical company, announces a U.S. distribution agreement for their Brain Armor® brand with Threshold® Enterprises, Ltd. This agreement allows Threshold to distribute Brain Armor® products throughout all 50 states in the U.S. Recognized as one of the largest manufacturers and distributors of nutritional supplements and other natural products, Threshold offers more than 450 brands, 18,000 products and distributes to 10,000+ retailers throughout the U.S. and Puerto Rico. This distribution agreement will greatly benefit Brain Armor® Inc., a Trident Brands subsidiary, in its ongoing efforts to achieve country wide distribution and continue its effort to be the market leader in the cognitive health supplement industry.“We are very pleased to have established a national distribution agreement with Threshold Enterprises, Ltd. Their experience and successful track record in distributing high quality supplements in the United States is well known and will be instrumental in growing the Brain Armor® brand as we continue to expand internationally. The entire Brain Armor team is very excited to work with Threshold to make Brain Armor® the brain supplement of choice,” says Mark Cluett, COO of Trident Brands Inc.“Threshold looks forward to representing Brain Armor® across our wide distribution network. We are very impressed with this state of the art brain health supplement line and their scientific and clinical approach. With the help of the entire team at Threshold, we believe that Brain Armor® will be a major player in the brain health supplement market,” says Threshold VP of Sales, Roy McDonald.About Brain Armor® Brain Armor is on a mission to improve cognitive health, well-being and performance at every stage of life and on every field of play. Our products are clinically-proven dietary supplements formulated with omega-3, healthy fats and vital nutrients, designed to support structural brain health and performance. Brain Armor products are vegetarian, made in the USA and are a regular part of many professional and elite amateur athlete and team conditioning programs. Brain Armor Inc. is a subsidiary of Trident Brands Incorporated (OTCQB: TDNT -- tridentbrands.com).For more information on Brain Armor®, please visit www.brain-armor.comAbout Threshold Enterprises, Ltd.Founded in 1978, Threshold Enterprises, Ltd, shares a vision to empower wellness on a global scale by providing fine-quality dietary supplements and nutritional education. Recognized as one of the largest manufacturers and distributors of nutritional supplements and other natural products, Threshold offers more than 450 brands and 18,000 products distributed throughout all 50 states, as well as in international markets. Threshold is dedicated to holistic healthcare, an approach based on treating the entire body, in an effort to achieve optimum wellness. With more than 40 years of experience, Threshold is an honored recipient of awards for the quality of its products, outstanding customer service, educational-based marketing, great deals and discounts, and a successful history of industry advocacy. For more information, please visit www.thresholdenterprises.comAbout Trident Brands, Inc.Trident Brands Incorporated is a publicly-traded nutraceutical company (OTCQB: TDNT), structured to rapidly develop private label, control label, brand label and proprietary ingredient platforms in the dynamic active nutrition, dietary supplement and functional ingredient categories. For more information, please visit www.tridentbrands.com.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable ...